ArticleFrontiers in nutrition2026
Association between estimated glucose disposal rate and metabolic syndrome in older adults with sarcopenia.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sarcopenia, an age-related syndrome marked by muscle mass and function decline, is closely linked to various adverse clinical outcomes. Insulin resistance (IR) has emerged as a pivotal link between sarcopenia and metabolic syndrome (MetS), significantly influencing their pathophysiological interactions. This study aimed to investigate the potential correlation between estimated glucose disposal rate (eGDR) and MetS among patients with sarcopenia, offering new insights into stratified prevention and treatment strategies. Methods: A total of 970 elderly individuals who visited the 921 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from January 2023 to December 2024 were enrolled. Participants were categorized into three groups, including the non-sarcopenia group ( Result: The prevalence of MetS in elderly individuals with sarcopenia was 14.01% (50/357), significantly higher than that of those without sarcopenia (3.10%, 19/613), with an odds ratio (OR) of 5.09 ( Conclusion: In the older adult group, patients with sarcopenia have a higher possibility of developing metabolic syndrome (MetS) compared with those without sarcopenia. In addition to lower eGDR levels, frailty, elevated uric acid, BMI, and MDA levels are associate with a higher prevalence of MetS in individuals with sarcopenia. Machine learning-based regression models outperform univariate screening models in predicting MetS risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.